Vilobelimab联合免疫调节剂治疗重症机械通气COVID-19的成本效果分析:PANAMO研究亚组分析
该研究基于PANAMO试验亚组,评估Vilobelimab联合标准治疗(含免疫调节剂)用于重症机械通气COVID-19患者的成本效果。模型显示Vilobelimab组总成本增加28,833美元,但获得额外3.65个QALY,ICER为7,892美元/QALY,在50,000美元/QALY阈值下具有成本效果。
要点
- Vilobelimab联合免疫调节剂较标准治疗可增加3.65个QALY,增量成本28,833美元。
- ICER为7,892美元/QALY,远低于常用支付意愿阈值50,000美元/QALY。
- 概率敏感性分析显示在超过98%的迭代中Vilobelimab联合方案更具成本效果。
核心结论
- 对于接受免疫调节剂治疗的重症机械通气COVID-19患者,Vilobelimab联合标准治疗具有成本效果。
研究设计与样本
- 基于PANAMO 3期试验亚组的成本效果分析,采用短期急性护理决策树和出院后2状态Markov队列模型,模拟终身时间跨度。
- 亚组中Vilobelimab组n=34,标准治疗组n=37,均接受过或同时使用免疫调节剂(托珠单抗或巴瑞替尼)。
主要发现
- Vilobelimab组总治疗成本为132,247美元,标准治疗组为103,414美元,增量成本28,833美元。
- Vilobelimab组获得9.71个QALY,标准治疗组获得6.05个QALY,增量3.65个QALY。
- Vilobelimab联合免疫调节剂相比标准治疗联合免疫调节剂的ICER为7,892美元/QALY。
- 概率敏感性分析中,在50,000美元/QALY支付意愿阈值下,超过98%的迭代支持Vilobelimab联合方案具有成本效果。
关键数值与推荐
- 28天全因死亡率:Vilobelimab联合免疫调节剂组为6.3%,标准治疗联合免疫调节剂组为40.9%(HR 0.13,95%CI 0.03-0.56,P=0.006)。
临床怎么用
- 对于重症机械通气且接受免疫调节剂的COVID-19患者,可考虑联合Vilobelimab以改善生存并具有成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The anti-C5a complement factor blocker vilobelimab (Gohibic) is authorized for emergency use by the US Food and Drug Administration for the treatment of hospitalized adults with COVID-19 when initiated within 48 hours of starting invasive mechanical ventilation or extracorporeal membrane oxygenation. In the PANAMO phase 3 trial of vilobelimab vs standard of care (SoC) (corticosteroids and antithrombotic agents), a post hoc analysis showed that prior and/or concomitant treatment with immunomodulators (tocilizumab or baricitinib) provided additional survival benefit with vilobelimab (n = 34) but not with SoC (n = 37). The point estimate for 28-day all-cause mortality for these groups was 6.3% vs 40.9% (hazard ratio, 0.13; 95% confidence interval, 0.03-0.56; P = 0.006). The current analysis evaluated the cost-effectiveness of vilobelimab vs SoC for the subgroup in the PANAMO study receiving immunomodulators. METHODS: A short-term acute care decision tree followed by a postdischarge 2-state Markov cohort model was used to estimate quality-adjusted life years (QALYs) and the incremental cost-effectiveness ratio (ICER) of the treatment arms. The model simulated progression from severe COVID-19 to survival or death over a lifetime. Outcomes data (COVID-19 all-cause mortality) were incorporated from PANAMO. Posthospitalization mortality was based on CDC age-specific survival data. Utility values and hospital costs came from the literature, and the cost of vilobelimab was obtained from Red Book online. RESULTS: The total cost of care was $103,414 with SoC and $132,247 with vilobelimab, with an incremental cost of $28,833. SoC provided 6.05 QALYs vs 9.71 QALYs for vilobelimab (3.65 additional QALYs). The ICER for vilobelimab compared to SoC, both with immunomodulators, was $7,892/QALY. Probabilistic sensitivity analysis demonstrated the robustness of the cost-effectiveness result, as vilobelimab + SoC was favored at a willingness-to-pay threshold of $50,000/QALY in over 98% of iterations. CONCLUSION: Vilobelimab therapy provides a cost-effective option to treat severely ill, mechanically ventilated patients with COVID-19 with prior and/or concomitant treatment with immunomodulators at a value well below the commonly accepted willingness-to-pay threshold of $50,000/QALY.
引用
- Malone DC, Seheult R, Brixner D, et al. The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study. Am J Health Syst Pharm. 2026. PMID: 40638782. doi:10.1093/ajhp/zxaf174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。